Zeldes & Haeggquist, LLP Announces Investigation of Palomar Medical Technologies, Inc. Acquisition by Cynosure, Inc.

Zeldes & Haeggquist, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into possible legal claims against the Board of Directors of Palomar Medical Technologies, Inc. (NASDAQ: PMTI), regarding possible breaches of fiduciary duties and other violations of law related to Palomar’s entry into an agreement to be acquired by Cynosure, Inc. (“Cynosure”) (NASDAQ: CYNO) in a transaction valued at approximately $294 million.

Zeldes & Haeggquist’s investigation concerns whether Palomar’s Board of Directors failed to adequately shop Palomar to obtain the best possible value for Palomar’s shareholders before entering into an agreement with Cynosure. Under the terms of the proposal, public shareholders of Palomar will receive $13.65 per share of Palomar common stock: $6.825 per share in cash and $6.825 per share in Cynosure common stock. According to Yahoo! Finance, at least one analyst has set a target price for Palomar stock at $14.50 per share.

If you own Palomar common stock and purchased your shares before March 18, 2013, and would like additional information regarding this investigation, or if you have information regarding the matters under investigation, please contact attorney Aaron M. Olsen or Amber L. Eck at 619-342-8000, or by email at [e-mail] or [e-mail].

Zeldes & Haeggquist is a full-service law firm which brings major class actions nationwide on behalf of defrauded investors and consumers and handles a variety of complex business litigation matters. Please visit www.zhlaw.com for more information.